Goodwin Procter advised EQRx on the deal while White & Case LLP advised CM Life Sciences III Inc. EQRx, Inc. announced its definitive merger agreement with CM […]
EQRx’s Merger with CM Life Sciences III
Kojin Therapeutics’ $60 Million Series A Financing
Goodwin Procter LLP advised Cathay Health, Polaris Partners, and Newpath Partners on the deal. Cathay Health, Polaris Partners, and Newpath Partners lead the Kojin Therapeutics’ $60 Million Series […]
Vascular Biogenics Ltd.’s $28.3 Million Shares Offering
Goodwin Procter LLP advised Vascular Biogenics Ltd. on the deal. Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT) announced the closing of its underwritten public offering […]